Competition is fierce for the first standard treatment as the second and third generation drugs, which are next-generation drugs, appear one after another in the ALK-positive non-small cell lung cancer treatment market. Target anticancer drugs targeting ALK mutations include the first generation Xalkori (Crizotinib), the second generation Zykadia (Ceritinib), "Alecensa (Alectinib HCl), and the third generation Lorviqua (Lorlatinib). A generational shift is taking place in Xalkori, which has long been the first standard treatment. Except for Lorviqua, which still has only secondary treatment indications, Roche's Alecensa and Takeda's Alunbrig are the most fiercely competitive drugs in Korea. Both are second-generation